Rifampin Pharmacokinetics and Safety in Preterm and Term Infants

Rifampin is active against methicillin-resistant staphylococcal species and tuberculosis (TB). We performed a multicenter, prospective pharmacokinetic (PK) and safety study of intravenous rifampin in infants of <121 days postnatal age (PNA). We enrolled 27 infants; the median (range) gestational...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Smith, P. Brian, Cotten, C. Michael, Hudak, Mark L., Sullivan, Janice E., Poindexter, Brenda B., Cohen-Wolkowiez, Michael, Boakye-Agyeman, Felix, Lewandowski, Andrew, Anand, Ravinder, Benjamin, Daniel K., Laughon, Matthew M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2019
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6535522/
https://ncbi.nlm.nih.gov/pubmed/30910891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00284-19
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados